Theravance Biopharma (TBPH) Profit After Tax (2013 - 2026)
Theravance Biopharma's (TBPH) quarterly Profit After Tax came in at -$4.9 million in Q1 2026, up 63.67% year-on-year from -$3.0 million in Q1 2025, and down 108.08% on a QoQ basis from $61.0 million in Q4 2025.
Theravance Biopharma (TBPH) Profit After Tax (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of Profit After Tax data on file, last reported at -$4.9 million in Q1 2026.
- On a quarterly basis, Profit After Tax rose 63.67% year-over-year to -$4.9 million in Q1 2026; TTM through Mar 2026 was $114.5 million, a 296.36% increase from a year earlier, with the FY2025 full-year figure at $105.9 million, up 287.7% from the prior year.
- Profit After Tax for Q1 2026 stood at -$4.9 million, down from $61.0 million in the prior quarter.
- Over the last five years, Profit After Tax for TBPH reached as high as $916.6 million in Q3 2022 and fell as low as -$41.5 million in Q1 2022.
- Historically, Profit After Tax has averaged $48.4 million across 5 years, with a median of -$12.7 million in 2024.
- Across the five-year window, Profit After Tax jumped 2696.1% in 2022 and tumbled 100.98% in 2023, its largest moves.
- Year by year, Profit After Tax stood at -$14.3 million in 2022, then surged by 40.31% to -$8.5 million in 2023, then slumped by 82.46% to -$15.5 million in 2024, then jumped by 493.02% to $61.0 million in 2025, then sank by 108.08% to -$4.9 million in 2026.
- Per Business Quant data, the three most recent Profit After Tax figures were -$4.9 million in Q1 2026, $61.0 million in Q4 2025, and $3.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Theravance Biopharma | 864.56 Mn | 469.90 Mn | - | -4.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.93 Mn |
| Dec 31, 2025 | 61.02 Mn |
| Sep 30, 2025 | 3.62 Mn |
| Jun 30, 2025 | 54.84 Mn |
| Mar 31, 2025 | -13.58 Mn |
| Dec 31, 2024 | -15.53 Mn |
| Sep 30, 2024 | -12.70 Mn |
| Jun 30, 2024 | -16.53 Mn |
| Mar 31, 2024 | -11.66 Mn |
| Dec 31, 2023 | -8.51 Mn |
| Sep 30, 2023 | -8.95 Mn |
| Jun 30, 2023 | -15.65 Mn |
| Mar 31, 2023 | -22.09 Mn |
| Dec 31, 2022 | -14.26 Mn |
| Sep 30, 2022 | 916.63 Mn |
| Jun 30, 2022 | -26.57 Mn |
| Mar 31, 2022 | -41.54 Mn |
| Dec 31, 2021 | -57.81 Mn |
| Sep 30, 2021 | -35.31 Mn |
| Jun 30, 2021 | -52.41 Mn |